8-K: Surrozen Collaboration with TCGFB Ends

Surrozen, Inc. announced the termination of its collaboration agreement with TCGFB, Inc., effective November 13, 2025, without penalties.

Summary

• Surrozen, Inc. received notice on October 14, 2025, from TCGFB, Inc. regarding the termination of their Collaboration Agreement, originally dated October 31, 2024.
• TCGFB exercised its right to terminate the agreement for convenience, with the termination becoming effective on November 13, 2025.
• Neither Surrozen nor TCGFB will incur any termination penalties as a result of this action.
• Under the agreement, Surrozen provided antibody discovery services and was eligible to receive up to $6.0 million in aggregate payments, plus third-party costs.
• Surrozen was also issued a warrant exercisable for up to 3.4 million shares of TCGFB common stock at an exercise price of $0.0001 per share, subject to certain vesting conditions.
• The Collaboration Agreement was considered a related party transaction due to affiliations with The Column Group, which holds over 5% of Surrozen's common stock and has a board member, Dr. Kutzkey, serving as its Managing Partner.

Sentiment

Score: 3

Explanation: The termination of a material collaboration agreement, which included potential revenue of $6.0 million and a significant warrant, is a clear negative event. While there are no penalties, the loss of future income and equity upside is detrimental. The related-party nature might also raise questions.

Positives

• The termination occurred for convenience, meaning no breach of contract by Surrozen.
• Neither party will incur any termination penalties, avoiding additional financial liabilities.

Negatives

• Loss of potential future revenue of up to $6.0 million from the collaboration agreement.
• Forfeiture of a warrant exercisable for up to 3.4 million shares of TCGFB common stock, which represented potential equity upside.
• Cessation of antibody discovery services for TCGFB, potentially impacting research and development activities or resource utilization.

Risks

• Loss of a significant revenue stream and potential equity upside from the terminated collaboration.
• Uncertainty regarding the future utilization of resources previously allocated to the TCGFB collaboration.
• Potential negative perception by investors regarding the stability of partnerships or the value of Surrozen's services.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance beyond the effective date of the termination. The impact of losing this revenue stream and warrant on future financial performance is implied but not quantified.

Industry Context

The termination of a collaboration agreement, especially one involving antibody discovery services, can signal shifts in strategic priorities for either party or challenges in the development pipeline. For Surrozen, it means the loss of a potential revenue stream and a partner in a competitive biotechnology landscape focused on novel therapies. The related-party nature of the agreement might raise questions about internal strategic alignment or the viability of projects backed by affiliated entities.

Related Party Transactions

• The Collaboration Agreement was a related party transaction because TCGFB was founded by The Column Group.
• Entities affiliated with The Column Group hold more than 5% of Surrozen's common stock.
• Dr. Kutzkey, a member of Surrozen's board of directors, serves as Managing Partner of The Column Group.

Stakeholder Impact

• Shareholders: Likely negative impact due to the loss of potential revenue and equity upside, which could affect future financial performance and share price.
• Employees: Potential reallocation of resources or personnel previously dedicated to the antibody discovery services for TCGFB.
• Customers/Partners: May raise questions about the stability or long-term viability of Surrozen's partnerships, though the termination was for convenience.

Next Steps

• The agreement's termination will become effective on November 13, 2025.

Key Dates

Recommendation

The termination of a material collaboration agreement, which included potential revenue of up to $6.0 million and a warrant for 3.4 million shares of TCGFB common stock, represents a significant loss of future financial upside for Surrozen. While no penalties were incurred, the cessation of this revenue stream and the forfeiture of the warrant are negative developments that could impact the company's financial outlook and investor confidence. This event suggests a reduction in the company's near-term growth prospects and potential value, warranting a cautious or negative stance on the stock.

Keywords

Surrozen, SRZN, TCGFB, Collaboration Agreement, Termination, Antibody Discovery, Biotechnology, SEC Filing, 8-K, Related Party Transaction, Warrant, The Column Group